AERRANE INHALATION ANAESTHETIC

Country: Singapore

Language: English

Source: HSA (Health Sciences Authority)

Active ingredient:

ISOFLURANE

Available from:

BAXTER HEALTHCARE (ASIA) PTE LTD

ATC code:

N01AB06

Dosage:

100.00%

Pharmaceutical form:

SOLUTION

Composition:

ISOFLURANE 100%

Administration route:

NASAL

Prescription type:

Prescription Only

Manufactured by:

Baxter Healthcare Corporation

Authorization status:

ACTIVE

Authorization date:

1996-04-19

Patient Information leaflet

Issued to the Medical Professionals Only 
AERRANE
 (Isoflurane USP) 
PRESENTATION 
AERRANE (isoflurane USP) is a colourless volatile liquid for inhalation,
containing 99.9% w/w 
isoflurane USP. 

INDICATIONS 
AERRANE (isoflurane) is a volatile halogenated anaesthetic
for general inhalation anaesthesia. 

DOSAGE AND ADMINISTRATION 
AERRANE (isoflurane) should be administered
only by persons trained in the administration of 
general anaesthesia.
Facilities for maintenance of a patent airway,
artificial ventilation, oxygen 
enrichment, and circulatory resuscitation must
be immediately available.  

AERRANE (isoflurane) is administered
by inhalation. AERRANE (isoflurane) should be 
delivered
from a vaporiser specifically designed for use with isoflurane . 

Dosage for induction and maintenance must be individualised and
titrated to the desired effect 
according to the patient’s age and clinical status.  

The need for premedication and type 
of premedicants must be determined on an individual 
basis. 

With the exception of neonates,
the minimum alveolar concentration (MAC) of AERRANE 
(isoflurane) decreases with increasing patient age. 

AERRANE (isoflurane) MAC values according to age as shown
below: 
AGE 
AVERAGE MAC VALUE 
IN 100% OXYGEN 
AVERAGE MAC VALUE IN 
30% OXYGEN AND 70% N
2
O 
0 – 1 month 
1.60% 
- 
1 – 6 months 
1.87% 
- 
6 – 12 months 
1.80% 
- 
1 – 5 years 
1.60% 
- 
19 – 30 years 
1.28% 
0.56% 
32 – 55 years 
1.15% 
0.50% 
55 – 83 years 
1.05% 
0.37% 

INDUCTION OF ANAESTHESIA 
If AERRANE (Iso
flurane) is used for induction
of anaesthesia, a starting concentration of 0.5% 
is recommended.
Concentrations of 1.3 – 3.0% usually bring about surgical anaesthesia within
7 
to 10 minutes. 
It is recommended
that use be made of a hypnotic dose of a short acting b

Summary of Product characteristics

PRESENTATION
AERRANE
(isoflurane
USP)
is
a
colourless
volatile
liquid
for
inhalation,
containing 99.9% w/w isoflurane USP.
INDICATIONS
AERRANE
(isoflurane)
is
a
volatile
halogenated
anaesthetic
for
general
inhalation anaesthesia.
DOSAGE AND ADMINISTRATION
AERRANE (isoflurane) should be administered only by persons
trained
in
the
administration
of
general
anaesthesia.
Facilities
for maintenance of a patent airway, artificial ventilation, oxygen
enrichment, and circulatory resuscitation must be immediately
available.
AERRANE (isoflurane) is administered by inhalation. AERRANE
(isoflurane)
should
be
delivered
from
a
vaporiser
specifically
designed for use with isoflurane .
Dosage for induction and maintenance must be individualised and
titrated to the desired effect according to the patient’s age and
clinical status.
The need for premedication and type of premedicants must be
determined on an individual basis.
With the exception of neonates, the minimum alveolar concentration
(MAC) of AERRANE (isoflurane) decreases with increasing patient
age.
AERRANE (isoflurane) MAC values according to age as shown
below:
AGE
AVERAGE MAC VALUE
IN 100% OXYGEN
AVERAGE MAC VALUE
IN 30% OXYGEN AND
70% N
2
O
0 – 1 month
1.60%
-
1 – 6 months
1.87%
-
6 – 12 months
1.80%
-
1 – 5 years
1.60%
-
19 – 30 years
1.28%
0.56%
32 – 55 years
1.15%
0.50%
55 – 83 years
1.05%
0.37%
INDUCTION OF ANAESTHESIA
If AERRANE (Isoflurane) is used for induction of anaesthesia, a
starting
concentration of 0.5% is recommended. Concentrations of 1.3 – 3.0%
usually
bring about surgical anaesthesia within 7 to 10 minutes.
It is recommended that use be made of a hypnotic dose of a short
acting
barbiturate or another product such as propofol, etomidate, or
midazolam
in order to avoid coughing or laryngospasm, which can arise if
induction is
carried out with AERRANE (isoflurane) alone or in combination with
oxygen or
with an oxygen-nitrous oxide mixture.When using AERRANE (isoflurane)
for
induction, it should be considered that the risk of coughing,